This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Module 2: Treatment of IPF: Guiding Patients Through Decisions

Module 2: Treatment of IPF: Guiding Patients Through Decisions

Format

Roundtable

Time to Complete

30 minutes

Released

December 29, 2016

Expires

December 29, 2017
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 CreditTM

Accredited Provider



Provided by the Academy for Continued Healthcare Learning

Commercial Supporter

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, Inc.

Program Description

Idiopathic pulmonary fibrosis (IPF) is a rare and fatal lung disease. Despite advances in the management of IPF and frequent interactions with varying members of the multidisciplinary management team, patients with IPF report frustrations and significant emotional consequences of their disease. Clinicians involved in the care of patients with IPF require education on rapid advances in pharmacologic and nonpharmacologic approaches to provide evidence-based care that helps patients live longer and experience improved quality of life. This educational activity is Module 2 of two 30-minute digital classroom activities to engage clinicians and ensure an effective educational activity. A patient education activity has been developed as well to help bridge the communication gap between clinicians and patients, while providing an educational resource specific for the patient and caregiver.

Intended Audience

This educational activity is designed for pulmonologists, respiratory nurses, respiratory therapists, and other clinicians interested in treatment advances for patients with IPF.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Evaluate the efficacy and safety data for pharmacotherapies used to treat IPF
  • Outline strategies for managing potential side effects across diverse patient populations
  • Counsel IPF patients and their families on pharmacologic and nonpharmacologic approaches and support strategies
  • Describe benefits of a multidisciplinary approach over the course of IPF

Conflict Of Interest Disclosure Policy

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.

Faculty

Kevin R. Flaherty, MD, MS
Professor of Medicine
Pulmonary/Critical Care
University of Michigan
Ann Arbor, MI

Dr. Flaherty discloses the following:
Consultant: Boehringer-Ingelheim and Genentech

Imre Noth, MD
Professor of Medicine
Director, Bronchoscopy
Director, Interstitial Lung Disease Program
The University of Chicago Medicine
Chicago, IL

Dr. Noth discloses the following:
Advisory Board, Honoraria Recipient and Speakers Bureau: Boehringer-Ingelheim and Genentech

Amy L. Olson, MD, MSPH
Assistant Professor
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

Dr. Olson discloses the following:
Advisory Board: Boehringer-Ingelheim
Speakers Bureau: Genentech

Accredited Provider Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Academy for Continued Healthcare Learning (ACHL) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Disclaimer

The content for this activity was developed independently of the commercial supporters. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Instructions

To obtain credit, a score of 75% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact:
Katlyn Cooper
Program Manager, ACHL
kcooper@achlcme.org
Add to Queue


Related to this activity